EL7.AI
StocksMedium•17 November 2026•
4 min read

SENTRY Results Show Spleen Reduction in 49.8%, While Karyopharm’s Outlook Remains Under Scrutiny

Key Facts

1At week 24, 49.8% of patients achieved a spleen-volume reduction of 35% or more with the combination therapy, compared with 28.0% with ruxolitinib alone.
2The initial review period for the application ended on October 27, 2026, on the 60th day.
3The SENTRY trial is testing a 60 mg weekly dose of selinexor in a plan covering 353 participants.
4Karyopharm expects to complete the restructuring transaction in the first quarter of 2027, subject to the terms.

On November 17, Karyopharm said the U.S. Food and Drug Administration had accepted its supplemental application for selinexor with ruxolitinib to treat myelofibrosis and set June 28, 2027, as its target decision date. The application follows the Phase 3 SENTRY trial, which showed that at week 24, 49.8% of patients receiving the combination achieved a reduction in spleen volume of 35% or more, compared with 28.0% with ruxolitinib alone. But the combined symptom measure did not reach statistical significance, with a p-value of 0.825. The company is relying on spleen-volume reduction as a potential surrogate for benefit in its regulatory effort. At the same time, Karyopharm is under Chapter 11 bankruptcy protection, placing the drug development news in the context of a corporate restructuring and risks to shareholders.

SENTRY is studying a 60 mg dose of selinexor once weekly alongside ruxolitinib, compared with placebo plus ruxolitinib. The trial plan included 353 patients with myelofibrosis who had not previously received JAK inhibitors and required platelet counts above 100 × 10^9 per liter. The trial therefore focuses on patients starting treatment without prior exposure to this drug class. The week 24 data announced by the company in June showed an advantage on the spleen-volume reduction measure, alongside a failure of the combined symptom measure to reach statistical significance. The application included data from SENTRY, the company said in its earlier disclosure.

Karyopharm said the accelerated approval pathway it is pursuing requires FDA agreement that a spleen-volume reduction of 35% or more is a reasonably likely surrogate for predicting overall survival. The company intends to use long-term survival data to verify clinical benefit, according to its statement. The initial review period for the application ended on October 27, the 60th day of review, according to the company’s filing with the U.S. Securities and Exchange Commission. The application’s progress therefore depends on the regulator’s assessment of the submitted evidence and its acceptance of this surrogate measure under the accelerated approval pathway. No final licensing decision was reported in that assessment.

Financial risks take on added importance amid the restructuring agreement Karyopharm announced with Ayrmid and its Chapter 11 bankruptcy protection filings. The company expects to complete the transaction in the first quarter of 2027, subject to the terms of the Chapter 11 plan. It also announced a commitment for up to $55 million in additional financing, saying the funding and cash generated from operations are expected to support continued operations during the proceedings. In its regulatory filing, the proposed plan stated that holders of common stock and convertible preferred stock would receive no payments or distributions on their securities. The company thus expected current equity investors to suffer a total loss.

The company also faces a change in its stock’s market status: Nasdaq halted trading in the common stock on November 11 and notified Karyopharm of its delisting, according to its SEC filing. The stock was then trading on the Pink market under the ticker KPTIQ. This comes as the company continues to develop its combination therapy application while restructuring proceedings advance in parallel with the regulatory process. Based on a 2023 Clarivate/DRG estimate, Karyopharm puts the number of people with myelofibrosis at about 20,000 in the United States and 17,000 in the European Union. The company describes the disease as a rare blood cancer.

Karyopharm is expected to present week 48 data from the SENTRY trial orally at the American Society of Hematology meeting on December 13, 2026. Data from the SENTRY-2 trial were also selected for an oral presentation on December 12. The week 48 follow-up will provide data over a longer period than the week 24 results the company announced in June. The upcoming presentation follows week 24 results that recorded the cited spleen-reduction rates, without statistical significance on the combined symptom measure. The company expects to complete the restructuring transaction in the first quarter of 2027, subject to fulfillment of the plan’s conditions.

Open on chart